Literature DB >> 3627289

Pharmacokinetic and neurochemical studies on N-propargyl-2-phenylethylamine, a prodrug of 2-phenylethylamine.

T S Rao, G B Baker, R T Coutts.   

Abstract

Pharmacokinetic and neurochemical properties of N-propargyl-2-phenylethylamine, a known MAO inhibitor and a potential prodrug of the bioactive trace amine, 2-phenylethylamine, were studied in rats. Intraperitoneal (i.p.) administration of N-propargyl-2-phenylethylamine produced marked elevations in 2-phenylethylamine levels in rat brain, blood and liver; these levels remained significantly above controls for more than 4 h. Neurochemical studies showed the drug to be a preferential MAO-B inhibitor at a dose of 0.1 mmol/kg (i.p.). This selectivity was much more pronounced in liver than in brain. N-Propargyl-2-phenylethylamine produced a significant decrease in whole brain concentrations of noradrenaline, dopamine and DOPAC, but they returned to control values by 3 h after drug administration. Concentrations of 5-HT were unaffected, while 5-HIAA and HVA concentrations increased significantly above controls. Results indicate that N-propargyl-2-phenylethylamine is a prodrug of 2-phenylethylamine and a potentially useful pharmacological tool with which to study the functional role of 2-phenylethylamine in the mammalian central nervous system.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3627289     DOI: 10.1007/BF00177747

Source DB:  PubMed          Journal:  Naunyn Schmiedebergs Arch Pharmacol        ISSN: 0028-1298            Impact factor:   3.000


  33 in total

1.  A SENSITIVE AND SPECIFIC ASSAY FOR THE ESTIMATION OF MONOAMINE OXIDASE.

Authors:  R J WURTMAN; J AXELROD
Journal:  Biochem Pharmacol       Date:  1963-12       Impact factor: 5.858

2.  The effect of monoamine oxidase inhibitors on some arylalkylamines in rate striatum.

Authors:  S R Philips; A A Boulton
Journal:  J Neurochem       Date:  1979-07       Impact factor: 5.372

3.  The monoamine oxidase inhibitors clorgyline and L-deprenyl also affect the uptake of dopamine, noradrenaline and serotonin by rat brain synaptosomal preparations.

Authors:  J C Lai; T K Leung; J F Guest; L Lim; A N Davison
Journal:  Biochem Pharmacol       Date:  1980-10-15       Impact factor: 5.858

4.  Uptake of beta-phenylethylamine in rat isolated lung.

Authors:  R R Ben-Harari; Y S Bakhle
Journal:  Biochem Pharmacol       Date:  1980-02-15       Impact factor: 5.858

5.  Metabolism distribution, and disappearance of injected beta-phenylethylamine in the rat.

Authors:  P H Wu; A A Boulton
Journal:  Can J Biochem       Date:  1975-01

6.  Electron-capture gas chromatographic analysis of beta-phenylethylamine in tissues and body fluids using pentafluorobenzenesulfonyl chloride for derivatization.

Authors:  G B Baker; T S Rao; R T Coutts
Journal:  J Chromatogr       Date:  1986-09-05

7.  N-(3-chloropropyl)phenylethylamine as a possible prodrug of beta-phenylethylamine: studies in the rat brain.

Authors:  T S Rao; G B Baker; R T Coutts
Journal:  Prog Neuropsychopharmacol Biol Psychiatry       Date:  1987       Impact factor: 5.067

8.  Non-selective inhibition of GABA and 5-HT uptake systems in rat brain by N-n-alkyl hydroxybenzylamine and N-n-alkyl phenylethylamine derivatives.

Authors:  C J Suckling; R J Breckenridge; S S Bansal; L C Williams; K J Watling; L L Iversen
Journal:  Biochem Pharmacol       Date:  1985-12-01       Impact factor: 5.858

9.  Molecular geometry of inhibitors of the uptake of catecholamines and serotonin in synaptosomal preparations of rat brain.

Authors:  B K Koe
Journal:  J Pharmacol Exp Ther       Date:  1976-12       Impact factor: 4.030

10.  Dopamine D2 receptors and dopamine metabolism. Relationship between biochemical and behavioural effects of substituted benzamide drugs.

Authors:  O Magnusson; C J Fowler; C Köhler; S O Ogren
Journal:  Neuropharmacology       Date:  1986-02       Impact factor: 5.250

View more
  1 in total

Review 1.  Prodrugs for amines.

Authors:  Ana L Simplício; John M Clancy; John F Gilmer
Journal:  Molecules       Date:  2008-03-03       Impact factor: 4.411

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.